Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-01-17
DOI
10.3389/fimmu.2017.01936
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
- (2017) Leisha A. Emens et al. EUROPEAN JOURNAL OF CANCER
- Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma
- (2017) Andrea Ferrario et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Molecular genetics and targeted therapy of WNT-related human diseases (Review)
- (2017) Masuko Katoh et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
- (2017) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
- (2017) Kurt Schönfeld et al. Journal of Hematology & Oncology
- Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia
- (2017) Manoj K. Kashyap et al. Journal of Hematology & Oncology
- Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
- (2017) Cynthia L. Gay et al. JOURNAL OF INFECTIOUS DISEASES
- Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types
- (2017) Athanasios Kotsakis et al. LANCET ONCOLOGY
- Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
- (2017) Elena Burova et al. MOLECULAR CANCER THERAPEUTICS
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
- (2017) E C Pietsch et al. Blood Cancer Journal
- Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
- (2017) Reed Friend et al. Drug Design Development and Therapy
- Targeting CD157 in AML using a novel, Fc-engineered antibody construct
- (2017) Christina Krupka et al. Oncotarget
- GRP78 at the Centre of the Stage in Cancer and Neuroprotection
- (2017) Caty Casas Frontiers in Neuroscience
- Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches
- (2017) Jeff Kamta et al. Frontiers in Oncology
- Antiproliferative and Apoptotic Effects of Novel Anti-ROR1 Single-Chain Antibodies in Hematological Malignancies
- (2017) Leili Aghebati-Maleki et al. SLAS Discovery
- The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells
- (2017) Patricia Macanas-Pirard et al. PLoS One
- Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)
- (2017) Yanyan Zhang et al. Scientific Reports
- Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
- (2017) Hyun Tae Lee et al. Scientific Reports
- APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
- (2016) Y.-T. Tai et al. BLOOD
- Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
- (2016) A. Jakubowiak et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma
- (2016) Noopur S. Raje et al. BRITISH JOURNAL OF HAEMATOLOGY
- Randomized phase 2 study of otlertuzumab and bendamustineversusbendamustine in patients with relapsed chronic lymphocytic leukaemia
- (2016) Tadeusz Robak et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lymphocyte-activation gene-3, an important immune checkpoint in cancer
- (2016) Yayi He et al. CANCER SCIENCE
- Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
- (2016) N. S. Raje et al. CLINICAL CANCER RESEARCH
- A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement
- (2016) L. Rasche et al. CLINICAL CANCER RESEARCH
- Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- (2016) Ranjana H. Advani et al. CLINICAL CANCER RESEARCH
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
- (2016) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
- (2016) Penka S. Petrova et al. CLINICAL CANCER RESEARCH
- Zevalin® (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?
- (2016) David Rizzieri CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia
- (2016) Michele Dal Bo et al. CURRENT CANCER DRUG TARGETS
- Targeting T Cell Co-receptors for Cancer Therapy
- (2016) Margaret K. Callahan et al. IMMUNITY
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
- (2016) Maria-Elisabeth Goebeler et al. JOURNAL OF CLINICAL ONCOLOGY
- The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking
- (2016) Marije B. Overdijk et al. JOURNAL OF IMMUNOLOGY
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib
- (2016) J Yu et al. LEUKEMIA
- EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia
- (2016) S Charmsaz et al. LEUKEMIA
- A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
- (2016) S Hipp et al. LEUKEMIA
- KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study
- (2016) Ronan T. Swords et al. LEUKEMIA RESEARCH
- A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells
- (2016) M. Broussas et al. MOLECULAR CANCER THERAPEUTICS
- ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
- (2016) M. J. Flynn et al. MOLECULAR CANCER THERAPEUTICS
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies
- (2016) Sheng-Bin Peng et al. PLoS One
- Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia
- (2016) Norbert Vey et al. Oncotarget
- A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia
- (2016) Neil E. Kay et al. Oncotarget
- The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
- (2016) Liesbeth Bieghs et al. Oncotarget
- T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
- (2016) Judith Feucht et al. Oncotarget
- Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma
- (2016) Nestor A Molfino et al. BMJ Open
- Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia
- (2016) Emily M. McWilliams et al. OncoImmunology
- Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
- (2015) Eunhee G. Kim et al. Biomolecules & Therapeutics
- Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
- (2015) M. Al-Hussaini et al. BLOOD
- Monoclonal antibodies in acute lymphoblastic leukemia
- (2015) E. Jabbour et al. BLOOD
- CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance
- (2015) Lauren A. Pitt et al. CANCER CELL
- First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70
- (2015) Taofeek Kunle Owonikoko et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia
- (2015) Carlos Cuesta-Mateos et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study
- (2015) P. Johnson et al. CLINICAL CANCER RESEARCH
- Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
- (2015) G. Gorgun et al. CLINICAL CANCER RESEARCH
- Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1
- (2015) Michael Y. Choi et al. Clinical Lymphoma Myeloma & Leukemia
- GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6
- (2015) L. Rasche et al. HAEMATOLOGICA
- Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
- (2015) L. Ruggeri et al. HAEMATOLOGICA
- Antitumor activity of an anti-CD98 antibody
- (2015) Gregory M. Hayes et al. INTERNATIONAL JOURNAL OF CANCER
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
- (2015) Maria Corinna A Palanca-Wessels et al. LANCET ONCOLOGY
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Genetic factors influencing the risk of multiple myeloma bone disease
- (2015) D C Johnson et al. LEUKEMIA
- Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
- (2015) M Pfeifer et al. LEUKEMIA
- Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial
- (2015) Luis Fayad et al. LEUKEMIA & LYMPHOMA
- Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys
- (2015) S Dudal et al. mAbs
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
- (2015) Marije B Overdijk et al. mAbs
- AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
- (2015) D. S. Pereira et al. MOLECULAR CANCER THERAPEUTICS
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma
- (2015) John E. Janik et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature
- (2015) Katherine Rybinski et al. Oncotarget
- Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway
- (2015) Manoj K. Kashyap et al. Oncotarget
- CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation
- (2015) Aldo M. Roccaro et al. Cell Reports
- Targeted Therapies in Adult B-Cell Malignancies
- (2015) Jean-François Rossi Biomed Research International
- GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6
- (2015) L. Rasche et al. HAEMATOLOGICA
- Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
- (2015) L. Ruggeri et al. HAEMATOLOGICA
- Tetraspanins as therapeutic targets in hematological malignancy: a concise review
- (2015) Kyle A. Beckwith et al. Frontiers in Physiology
- The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia
- (2015) Julia Christine Gutjahr et al. Frontiers in Immunology
- Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges
- (2015) Maria Vela et al. Frontiers in Immunology
- Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study
- (2015) Paul G Richardson et al. Lancet Haematology
- Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib
- (2015) Paul J Neeson et al. OncoImmunology
- Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model
- (2015) De-Kuan Chang et al. OncoImmunology
- A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies
- (2015) Hélène Sicard et al. OncoImmunology
- Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
- (2015) Jie Liu et al. PLoS One
- Chemokines in tumor progression and metastasis
- (2015) Purvaba J. Sarvaiya et al. Oncotarget
- A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
- (2014) Robert Z. Orlowski et al. AMERICAN JOURNAL OF HEMATOLOGY
- A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia
- (2014) J. C. Byrd et al. BLOOD
- A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL
- (2014) J. A. Woyach et al. BLOOD
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
- (2014) J. San-Miguel et al. BLOOD
- Immunotoxins for leukemia
- (2014) A. S. Wayne et al. BLOOD
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
- (2014) S. Gill et al. BLOOD
- Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF- B mediates chemoresistance
- (2014) R. Jacamo et al. BLOOD
- Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
- (2014) A Patnaik et al. BRITISH JOURNAL OF CANCER
- Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™therapeutic protein, for relapsed or refractory NHL patients
- (2014) John M. Pagel et al. BRITISH JOURNAL OF HAEMATOLOGY
- IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma
- (2014) A. Marie-Cardine et al. CANCER RESEARCH
- Anti-CCR4 Monoclonal Antibody Mogamulizumab for the Treatment of EBV-Associated T- and NK-Cell Lymphoproliferative Diseases
- (2014) T. Kanazawa et al. CLINICAL CANCER RESEARCH
- Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome
- (2014) X. Ni et al. CLINICAL CANCER RESEARCH
- A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors
- (2014) L. A. Diaz et al. CLINICAL CANCER RESEARCH
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer
- (2014) R. A. Previs et al. CLINICAL CANCER RESEARCH
- Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma
- (2014) Jonathan L. Berkowitz et al. CLINICAL IMMUNOLOGY
- Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma
- (2014) John D. Hainsworth et al. Clinical Lymphoma Myeloma & Leukemia
- Elotuzumab for the treatment of multiple myeloma
- (2014) Philippe Moreau et al. Future Oncology
- CCR4 and its ligands: from bench to bedside
- (2014) O. Yoshie et al. INTERNATIONAL IMMUNOLOGY
- Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma
- (2014) Nizar M. Tannir et al. INVESTIGATIONAL NEW DRUGS
- Denosumab for Treatment of Hypercalcemia of Malignancy
- (2014) Mimi I. Hu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization
- (2014) Luis-Alberto Pérez-Quintero et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy
- (2014) A. Kretz-Rommel et al. JOURNAL OF IMMUNOLOGY
- Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC
- (2014) S J Busfield et al. LEUKEMIA
- The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model
- (2014) K A Beckwith et al. LEUKEMIA
- IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors
- (2014) M Jourdan et al. LEUKEMIA
- A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia
- (2014) Simon Z. He et al. LEUKEMIA & LYMPHOMA
- Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts
- (2014) Sonia Chamorro et al. mAbs
- Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells
- (2014) Huaijian Guo et al. MOLECULAR AND CELLULAR BIOLOGY
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- 177Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice
- (2014) Ada H. V. Repetto-Llamazares et al. PLoS One
- Potential role of daratumumab in the treatment of multiple myeloma
- (2014) Tomer Mark et al. OncoTargets and Therapy
- Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
- (2014) A Ehninger et al. Blood Cancer Journal
- Effects of RANKL-Targeted Therapy in Immunity and Cancer
- (2014) Michael L. Cheng et al. Frontiers in Oncology
- GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
- (2013) E. Padron et al. BLOOD
- Monoclonal antibody targeting of IL-3 receptor with CSL362 effectively depletes CML progenitor and stem cells
- (2013) E. Nievergall et al. BLOOD
- Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia
- (2013) N. Yaktapour et al. BLOOD
- The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization
- (2013) J. Hoellenriegel et al. BLOOD
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy
- (2013) Y.-T. Hsieh et al. BLOOD
- In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma
- (2013) Samantha Pozzi et al. BONE
- Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma
- (2013) Michelle Fanale et al. BRITISH JOURNAL OF HAEMATOLOGY
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer
- (2013) Kouichirou Aida et al. CANCER SCIENCE
- Monoclonal antibodies in treatment of multiple sclerosis
- (2013) P. S. Rommer et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Long-Term Follow-Up of R-CHOP With Bevacizumab as Initial Therapy for Mantle Cell Lymphoma: Clinical and Correlative Results
- (2013) Jia Ruan et al. Clinical Lymphoma Myeloma & Leukemia
- The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity
- (2013) Fabien B. Vincent et al. CYTOKINE & GROWTH FACTOR REVIEWS
- CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia
- (2013) Ye Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma
- (2013) Beatriz Somovilla-Crespo et al. Journal of Hematology & Oncology
- At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
- (2013) Andrew M. Intlekofer et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
- (2013) D Atanackovic et al. LEUKEMIA
- Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies
- (2013) Sarwish Rafiq et al. mAbs
- ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
- (2013) Karen Silence et al. mAbs
- Granulocyte–macrophage colony-stimulating factor: not just another haematopoietic growth factor
- (2013) Alejandro Francisco-Cruz et al. MEDICAL ONCOLOGY
- Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML
- (2013) E. A. R. Sison et al. MOLECULAR CANCER RESEARCH
- The Natural Human IgM Antibody PAT-SM6 Induces Apoptosis in Primary Human Multiple Myeloma Cells by Targeting Heat Shock Protein GRP78
- (2013) Leo Rasche et al. PLoS One
- Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44
- (2013) S. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
- (2013) D. Sugiyama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Engineered SIRP Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
- (2013) K. Weiskopf et al. SCIENCE
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- VEGF isoforms
- (2013) Martine Perrot-Applanat Cell Adhesion & Migration
- Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial
- (2013) F. Chowdhury et al. Cancer Immunology Research
- Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies
- (2012) Ira V. Gupta et al. Annals of the New York Academy of Sciences
- A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
- (2012) A. T. Stopeck et al. BLOOD
- Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)
- (2012) G. J. Ossenkoppele et al. BLOOD
- How I treat prolymphocytic leukemia
- (2012) C. Dearden BLOOD
- A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
- (2012) N. Vey et al. BLOOD
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
- (2012) D. M. Benson et al. BLOOD
- A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
- (2012) William Bensinger et al. BRITISH JOURNAL OF HAEMATOLOGY
- Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals
- (2012) Rosa Lapalombella et al. CANCER CELL
- Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study
- (2012) Carmen D. Schweighofer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
- (2012) Timothy S. Fisher et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia
- (2012) B. J. Schmiedel et al. CANCER RESEARCH
- Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
- (2012) Ivetta Danylesko et al. Clinical & Developmental Immunology
- BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies
- (2012) M. R. Kuhne et al. CLINICAL CANCER RESEARCH
- Obinutuzumab for the treatment of lymphoproliferative disorders
- (2012) Carolyn Owen et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- CD98 at the crossroads of adaptive immunity and cancer
- (2012) J. M. Cantor et al. JOURNAL OF CELL SCIENCE
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
- (2012) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Crosstalk between Human IgG Isotypes and Murine Effector Cells
- (2012) M. B. Overdijk et al. JOURNAL OF IMMUNOLOGY
- Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
- (2012) D Kim et al. LEUKEMIA
- Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
- (2012) Andres Forero-Torres et al. LEUKEMIA & LYMPHOMA
- Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
- (2012) John C. Byrd et al. LEUKEMIA & LYMPHOMA
- Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells
- (2012) D.-K. Chang et al. MOLECULAR CANCER THERAPEUTICS
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human Anti-CCR4 Minibody Gene Transfer for the Treatment of Cutaneous T-Cell Lymphoma
- (2012) Thomas Han et al. PLoS One
- The pros and cons of chemokines in tumor immunology
- (2012) Antonella Viola et al. TRENDS IN IMMUNOLOGY
- EPHA3 as a novel therapeutic target in the hematological malignancies
- (2012) Niamh Keane et al. Expert Review of Hematology
- Targeting Chemokine Receptor CCR4 in Adult T-Cell Leukemia-Lymphoma and Other T-Cell Lymphomas
- (2012) Kensei Tobinai et al. Current Hematologic Malignancy Reports
- Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy
- (2011) M. P. Chao et al. BLOOD
- Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas
- (2011) M. Guadagnoli et al. BLOOD
- A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies
- (2011) K.-H. Heider et al. BLOOD
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo
- (2011) Elizabeth Ward et al. BRITISH JOURNAL OF HAEMATOLOGY
- The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
- (2011) Klaus Podar et al. BRITISH JOURNAL OF HAEMATOLOGY
- Distinct Apoptotic Signaling Characteristics of the Anti-CD40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non-Hodgkin Lymphoma
- (2011) T. S. Lewis et al. CLINICAL CANCER RESEARCH
- Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
- (2011) M. Steiner et al. CLINICAL CANCER RESEARCH
- CXCL12 (SDF1 )-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
- (2011) D. G. Duda et al. CLINICAL CANCER RESEARCH
- Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma
- (2011) D. Vishwamitra et al. HAEMATOLOGICA
- Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
- (2011) Simona Lapusan et al. INVESTIGATIONAL NEW DRUGS
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
- (2011) P Moreau et al. LEUKEMIA
- NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice
- (2011) C I-U Chen et al. LEUKEMIA
- Epratuzumab-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies
- (2011) R. M. Sharkey et al. MOLECULAR CANCER THERAPEUTICS
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
- (2011) Christian Steidl et al. NATURE
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Tumor angiogenesis: molecular pathways and therapeutic targets
- (2011) Sara M Weis et al. NATURE MEDICINE
- CD47-signal regulatory protein- (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction
- (2011) X. W. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies
- (2011) M S van der Veer et al. Blood Cancer Journal
- Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia
- (2011) J. A. Burger Hematology-American Society of Hematology Education Program
- Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
- (2010) F. Morschhauser et al. ANNALS OF ONCOLOGY
- Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration
- (2010) J. Moreaux et al. BLOOD
- Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia
- (2010) J. Wang et al. BLOOD
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
- (2010) A Younes et al. BRITISH JOURNAL OF CANCER
- Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
- (2010) Mark P. Chao et al. CANCER RESEARCH
- Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
- (2010) Kensei Tobinai et al. CANCER SCIENCE
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma
- (2010) T. Ishii et al. CLINICAL CANCER RESEARCH
- CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
- (2010) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Renal function in newly diagnosed multiple myeloma - A demographic study of 1353 patients
- (2010) Lene Meldgaard Knudsen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Galiximab: a review
- (2010) Seema Bhat et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
- (2010) M. Hussein et al. HAEMATOLOGICA
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma
- (2010) Kazuhito Yamamoto et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
- (2010) Richard R. Furman et al. LEUKEMIA & LYMPHOMA
- Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia
- (2010) Tait Shanafelt et al. LEUKEMIA & LYMPHOMA
- Monoclonal antibody therapy in multiple sclerosis
- (2010) Paulo Fontoura mAbs
- Therapeutic antibody targeting of individual Notch receptors
- (2010) Yan Wu et al. NATURE
- Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma
- (2010) L. POUR et al. NEOPLASMA
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of Notch1 Antibodies That Inhibit Signaling of Both Normal and Mutated Notch1 Receptors
- (2010) Miguel Aste-Amézaga et al. PLoS One
- Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21
- (2010) J. D. Shields et al. SCIENCE
- An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma
- (2009) Ravi Vij et al. AMERICAN JOURNAL OF HEMATOLOGY
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
- (2009) M. Fulciniti et al. BLOOD
- A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies
- (2009) Pina M. Cardarelli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection
- (2009) Markus Moll et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody
- (2009) N. Chapuis et al. HAEMATOLOGICA
- Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
- (2009) Yanping Hu et al. IMMUNOLOGY
- Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
- (2009) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
- (2009) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
- (2009) Luis H. Camacho et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
- (2009) Ranjana Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
- (2009) Daniel Hirschhorn-Cymerman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- (2009) F. van Rhee et al. MOLECULAR CANCER THERAPEUTICS
- Tumor-mediated liver X receptor-α activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses
- (2009) Eduardo J Villablanca et al. NATURE MEDICINE
- Glycosylation as a strategy to improve antibody-based therapeutics
- (2009) Roy Jefferis NATURE REVIEWS DRUG DISCOVERY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
- (2008) M. Luqman et al. BLOOD
- CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia
- (2008) A. W. Ho et al. BLOOD
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
- (2008) Z. Zeng et al. BLOOD
- APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells
- (2008) E. Belnoue et al. BLOOD
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
- Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
- (2008) E Oflazoglu et al. BRITISH JOURNAL OF CANCER
- Anti-CD20 monoclonal antibody therapy in multiple myeloma
- (2008) Prashant Kapoor et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy
- (2008) Kenji Ishitsuka et al. BRITISH JOURNAL OF HAEMATOLOGY
- Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
- (2008) Li Yang et al. CANCER CELL
- Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
- (2008) A. Natsume et al. CANCER RESEARCH
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
- l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms
- (2008) Kyoichi Kaira et al. CANCER SCIENCE
- Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia
- (2008) S. Baskar et al. CLINICAL CANCER RESEARCH
- Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
- (2008) J. A. McEarchern et al. CLINICAL CANCER RESEARCH
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
- CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia
- (2008) D. Rossi et al. HAEMATOLOGICA
- Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL*
- (2008) Paul J Kostenuik et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
- (2008) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress
- (2008) Robert K. Oldham et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started